Neuropath Evid of Graft Survival & Striatal Reinnerva after Transpl of Fetal Mesencephalic Tissue in Parkinson's Dis
NEJM 332:1118-1124, 11631995., Kordower,J.H.,et al, 1995
Bilateral Fetal Nigral Transplantation Into the Postcommissural Putamen in Parkinson's Disease
Ann Neurol 38:379-388, Freemen,T.B.,et al, 1995
Stereotactic Ventral Pallidotomy for Parkinson's Disease
Neurol 45:753-761, Dogali,M.,et al, 1995
Electroconvulsive Therapy for the Physical Signs of Parkinson's Disease Without Depressive Disorder
JNNP 58:641-642, Pridmore,S.,et al, 1995
Psychosis in Advanced Parkinson's Disease:Treatment with Ondansetron, a 5-HT3 Receptor Antagonist
Neurol 45:1305-1308, Zoldan,J.,et al, 1995
Parkinsonism Unmasked by Lovastatin
Ann Neurol 37:685-686, Muller,T.,et al, 1995
Psychogenic Parkinsonism
Arch Neurol 52:802-810, Lang,A.E.,et al, 1995
Increased Incidence of Levodopa Therapy Following Metoclopramide Use
JAMA 274:1780-1782, Avorn,J.,et al, 1995
Dopa-Responsive parkinsonism Phenotype of Machado-Jospeh Disease:Confirmation of 14q CAG Expansion
Ann Neurol 48:684-687, Tuite,P.J.,et al, 1995
An Algorithm for the Management of Parkinson's Disease
Neurol 44:S1-S52, Koller,W.C.,et al, 1994
Increased Risk of Parkinson's Disease in Parents and Siblings of Patients
Ann Neurol 36:659-661, Payami,H.,et al, 1994
Assessment of Fetal Tissue Transplantation in Parkinson's Disease:Does PET Play a Role
Neurol 44:1777-1780, Martin,W.R.W.&Perlmutter,J.S., 1994
MRI of Transient Postencephalitic Parkinsonism
J Comput Assist Tomogr 18:155-159, Shen,W.,et al, 1994
Evidence for Long-Term Survival and Function of Dopaminergic Grafts in Progressive Parkinson's Disease
Ann Neurol 35:172-180, Lindvall,O.,et al, 1994
Clozapine:A 2-year Open Trial in Parkinson's Disease Patients with Psychosis
Neurol 44:544-546, Factor,S.A.,et al, 1994
Extrapyramidalism in Alzheimer's Disease:Prevalence, Psychiatric and Neuropsychological Correlates
JNNP 57:1503-1509, Merello,M.,et al, 1994
Post-Traumatic Movement Disorders:Central and Peripheral Mechanisms
Neurol 44:2006-2014, Jankovic,J., 1994
Botulinum Toxin-A Improves the Rigidity of Progressive Supranuclear Palsy
Ann Neurol 35:237-239, Polo,K.B.&Jabbari,B., 1994
Physical Therapy and Parkinson's Disease:A Controlled Clinical Trial
Neurol 44:376-378, Comella,C.L.,et al, 1994
Progressive Supranuclear Palsy:Neuropathologic and Clinical Heterogeneity
Neurol 44:1015-1024, Gearing,M.,et al, 1994
The Syndrome of'Pure Akinesia'and Its Relationship to Progressive Supranuclear Palsy
Neurol 44:1025-1029, Riley,D.E.,et al, 1994
The Relationship of Essential Tremor to Other Movement Disorders:Report on 678 Patients
Ann Neurol 35, 717-7231994., Koller,W.C.,et al, 1994
Clinical Assessment of Extrapyramidal Signs in Nursing Home Patients Given Antipsychotic Medication
Arch Int Med 154:1113-1117, Avorn,J.,et al, 1994
Levodopa Failure in Chronic Manganism
Neurol 44:1600-1602, 15831994., Lu,C-S.,et al, 1994
Reversal of Amphotericin-B-Related Encephalopathy
Neurol 44:1183-1184, Balmaceda,C.M.,et al, 1994
Oxidative Damage in Neurodegenerative Disease
Lancet 344:796-798, Jenner,P., 1994
Dopa-Responsive Dystonia:Pathological and Biochemical Observations in a Case
Ann Neurol 35:396-402, 3811994., Rajput,A.H.,et al, 1994
Eye Movements in Parkinsonian Syndromes:Vidailhet
M. , et al, Neurol 35:420-42694., , 1994
A Multicenter Double-Blind Placebo-Controlled Trial of Pergolide as an Adjunct to Sinemet in Parkinson's Disease
Movement Disorders, 9:40-471994., Olanow,C.W.,et al, 1994
Sleep Disruption in Parkinson's Disease:Assessment by Continuous Activity Monitoring
Arch Neurol 51:922-928, vanHilten,B.,et al, 1994
Diff Diag of parkinson's Disease, Multiple Sys Atrophy, & Steele-Richardson-Olszewski Syndrome:Striatal F-Dopa PET Data
JNNP 57:278-284, Burn,D.J.,et al, 1994
Four-Year Follow-up of Adrenal-to-Brain Transplants in Parkinson's Disease
Arch Neurol 51:559-563, Diamond,S.G.,et al, 1994
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Therapy of Patients with Parkinson's Disease
Arch Neurol 51:754-756, Paulson,G.W., 1994
Parkinsonism Induced by Solvent Abuse
Ann NEurol 35:616-618, Uitti,R.J.,et al, 1994
Parkinsonism Caused by Petroleum Waste Ingestion
Neurol 44:1051-1054, Tetrud,J.W.,et al, 1994
Preliminary NINDS Neuropathologic Criteria for Steele-Richardson-Olszewski Syndrome (Progressive Supranuclear Palsy)
Neurol 44:2015-2019, Hauw,J.-J., 1994
Fluctuating Parkinson's Disease:Treatment with the Long-Acting Dopamine Agonist Cabergoline
Arch Neurol 51:1236-1241, Ahlskog,J.E.,et al, 1994
Patient Education and Health Promotion Can Be Effective in Parkinson's Disease:A Randomized Controlled Trial
Am J Med 97:429-435, Montgomery,E.B.,et al, 1994
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Parkinsonism Unmasked by Verapamil
Clinical Neuropharmacol 16:263-265, Garcia-Albea,E.,et al, 1993
Gene Therapy for Neurologic Disease
Arch Neurol 50:1252-1268, Suhr,S.T.&Gage,F.H., 1993
Autosomal Dominant Parkinsoniam with Benign Course and Typical Lewy-Body Pathology
Neurol 43:2222-2227, Golbe,L.I.,et al, 1993
Risk Factors for Nursing Home Placement in Advanced Parkinson's Disease
Neurol 43:2227-2229, Goetz,C.G.&Stebbins,G.T., 1993
Fatigue in Parkinson's Disease
Neurol 43:2016-2018, Friedman,J.&Friedman,H., 1993
Cabergoline in Parkinson's Disease:Long-Term Follow-up
Neurol 43:2587-2590, Lera,G.,et al, 1993
Multictr Study of Cabergoline, A Long-Acting Dopamine Receptor Agonist, in PD Fluct Resp to Levodopa/Carbidopa
Neurol 43:1981-1984, Lieberman,A.,et al, 1993
Neurosurgical Horizons in Parkinson's Disease
Neurol 43:1-7, Goetz,C.G.,et al, 1993
A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Arch Neurol 50:140-148, Hughes,A.J.,et al, 1993
Increase of Parkinson Disability after Fluoxetine Medication
Neurol 43:211-213, Steur,E.N.H.J., 1993